New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
04:55 EDTALKS, ALKS, RGDO, RGDO, LXRX, LXRX, ZIOP, ZIOP, RNA, RNA, AUXL, AUXL, XON, XON, SIGA, SIGA, GALE, GALE, MSTX, MSTXBiotech Industry Organization to hold a conference
16h Annual BIO CEO & Investor Conference is being held in New York on February 10-11.
News For ALKS;GALE;SIGA;XON;AUXL;RNA;ZIOP;LXRX;RGDO;MSTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
February 9, 2016
09:07 EDTALKSAlkermes CEO remains optimistic on depression drug, Forbes reports
Subscribe for More Information
07:10 EDTZIOP, XONZIOPHARM says first patient enrolled in Phase 1 study of CAR T-Cell therapy
ZIOPHARM Oncology (ZIOP) announced that the first patient has been enrolled in a Phase 1 clinical study of its second generation non-viral CD19-specific chimeric antigen receptor modified T-cell therapy in patients with advance lymphoid malignancies. The CD19-specific T cells were modified using the Sleeping Beauty system to stably express the CAR in T cells. The Sleeping Beauty transposon-transposase is a unique non-viral system for introducing genes encoding CARs and T-cell receptors into lymphocytes and is exclusively licensed by Intrexon Corporation (XON) through The University of Texas MD Anderson Cancer Center and accessed as part of ZIOPHARM's collaboration.
February 8, 2016
07:25 EDTGALEBiotech Industry Organization to hold a conference
Subscribe for More Information
07:13 EDTGALEGalena receives notice of allowance of U.S. patent for NeuVax
Galena Biopharma announced the United States Patent Office issued a Notice of Allowance for an additional U.S. patent application covering multiple uses of NeuVax. NeuVax is a peptide immunotherapy currently being evaluated for the prevention of cancer recurrence and is Galena's lead development agent in multiple ongoing and planned clinical trials. This patent will expand both the protection and the potential population of cancer patients NeuVax may address. Once issued, the patent will expire in 2028, not including any patent term extensions.
February 5, 2016
07:51 EDTALKSWoodford calls Alkermes, Prothena selloffs 'greatly overdone'
British businessman Neil Woodford's Woodford Investment Management said it added to Alkermes (ALKS) and Prothena (PRTA) positions at what it considers to be "extremely attractive valuation levels." In its January letter to investors, the fund says the recent share price moves "look greatly overdone." Woodford also sold its position in GlaxoSmithKline (GSK) and initiated a new stake in Theravance Biopharma (TBPH). The company "retains a valuable economic interest in the future commercial potential of the respiratory franchise being developed in partnership with GlaxoSmithKline," the fund wrote. It also has "some very interesting, albeit earlier-stage, assets in therapeutic areas such as chronic obstructive pulmonary disease, cardiovascular & renal disease," it added. Woodford made no mention of Northwest Biotherapeutics (NWBO) in the letter, a company he invested in last year. Woodford Investment Management, established in 2014, describes itself as the "the opportunity for Neil Woodford, one of the UK's most highly-regarded fund managers, to distil his 30 years of experience and learning into a business founded on his own principles." Reference Link
February 3, 2016
07:38 EDTXONIntrexon jumps after Bill Miller says second largest position
LMM founder Bill Miller said on CNBC that Intrexon (XON) is his firm's second largest position. Amazon.com (AMZN) is LMM's largest position, Miller told viewers. Shares of Intrexon are up 4% to $32.00 in pre-market trading following Miller's comments.
February 2, 2016
14:52 EDTXONZika virus acquired through sexual transmission reported in Dallas
Dallas County Health and Human Services announced it has received confirmation from the Centers for Disease Control and Prevention of the first Zika virus case acquired through sexual transmission in Dallas County in 2016. The patient was infected with the virus after having sexual contact with an ill individual who returned from a country where Zika virus is present, DCHHS reported. Publicly traded companies working on combating Zika include Inovio (INO), Cerus (CERS), NewLink (NLNK) and Intrexon (XON).
12:56 EDTXONMizuho downplays near-term Zika revenue potential for NewLink, Intrexon
The Zika virus and its link to microcephaly and fetal brain damage have exploded into public view and lead to several drugmakers announcing plans to fight the disease, but Mizuho analyst Eric Criscuolo downplayed the potential for Zika to truly move the needle for companies in the space in the near-term. PERIPHERAL OPPORTUNITIES: NewLink (NLNK) announced plans to develop treatment options for the Zika virus as the disease was declared a global health emergency by the World Health Organization this week. While the company "could" secure funding and partnerships for the project, Criscuolo does not view NewLink's Zika plans as core to its investment story, encouraging investors to instead evaluate the company on the basis of its HyperAcute and IDO programs. Meanwhile, Intrexon's (XON) efforts in mosquito population control have also gained attention amid the rise of Zika, whose primary transmission vector is the mosquito. Though even a small slice of global mosquito spending would represent "significant" revenue for Intrexon, Criscuolo cautions that the company's program is still in early stages, with attempts at a wider rollout likely encountering political, biological, financial and public opinion hurdles. Separately, the analyst said he wouldn't be surprised to see OraSure (OSUR) also attempt to develop a Zika test given the company's response to Ebola last year, though as with NewLink, Criscuolo believes any such effort would be peripheral to OraSure's primary businesses. OTHERS TO WATCH: Other publicly traded companies involved in combating Zika include Inovio (INO) and Cerus (CERS). PRICE ACTION: Shares of NewLink are up roughly 5% to $25.63. Meanwhile, Intrexon has slipped 5.5% on Tuesday afternoon but is still up 15% over the last five trading days. Among others with links to Zika, OraSure is up fractionally, Inovio has fallen 7% and Cerus has dipped 1.4% this afternoon.
08:59 EDTALKSLeerink views doc checks as positive for ACADIA, Neurocrine
Subscribe for More Information
February 1, 2016
13:42 EDTXONWHO declares Zika virus to be global emergency, Reuters reports
Subscribe for More Information
10:08 EDTGALEHigh option volume stocks
High option volume stocks: NOK HLT NCLH DF GALE VMW DPS SYY SYMC PGR
09:27 EDTMSTXOn The Fly: Pre-market Movers
HIGHER: Alere (ALR), up 45.4% after announcing that Abbott (ABT) will acquire the company for $56 per share... Questar (STR), up 20.2% after announcing that Dominion (D) will acquire the company for $25 per share and assumed debt... Mast Therapeutics (MSTX), up 12.2% after the Phase 2a study of AIR001 met its primary endpoint... Twitter (TWTR), up 5.7% after The Information reported that Marc Andreessen and Silver Lake have considered a deal for Twitter... Herbalife (HLF), up 2.2% after the Wall Street Journal reported that probes into Bill Ackman's "pyramid scheme" accusations against Herbalife, as well as Herbalife's own accusations that Ackman sought to manipulate the company's stock, have both failed to uncover enough evidence to support criminal charges. LOWER: Dominion Resources, down 1.7% after reporting quarterly results and that it will acquire Questar... Abbott, down 4.1% after announcing that it will acquire Alere... GoPro (GPRO), down 4.4% after Piper Jaffray cut its price target to $7.50.
07:41 EDTMSTXMast Therapeutics Phase 2a study of AIR001 met primary endpoint
Subscribe for More Information
07:17 EDTXONZika gives Intrexon a significant opportunity, says Stifel
Subscribe for More Information
06:08 EDTXONIntrexon volatility increases; working on combating Zika
Intrexon February call option implied volatility is at 88, March is at 77; compared to its 52-week range of 45 to 107; suggesting large price movement as the company works on genetically modifying male mosque toys so that their offspring die young.
January 29, 2016
07:59 EDTALKSAlkermes management to meet with JPMorgan
Subscribe for More Information
January 28, 2016
16:40 EDTXONOn The Fly: Top stock stories for Thursday
The Dow began the session with triple digit gains thanks in part to solid earnings reports from some of America's bellwether corporations and oil prices, which approached $34 a barrel. The market was unable to hold its opening gains and eventually crossed into negative territory. Before the losses became too big the averages reversed and moved back across the flat line. With oil holding onto its gains and closing above $33 a barrel, the averages closed in positive territory ahead of the next barrage of earnings reports. ECONOMIC EVENTS: In the U.S., initial jobless claims fell to 278,000 last week, versus the expected 281,000 first-time claims. Durable goods orders dropped 5.1% in December, versus expectations for a decrease of 0.7%. The core reading, which removes transportation items, was down 1.2%, versus expectations for a decline of 0.1%. The National Association of Realtors' pending home sales index for December rose 0.1%, versus expectations for it to be up 0.9%. COMPANY NEWS: Shares of Facebook (FB) surged 15.5% to $109.11 after the social media giant's fourth quarter earnings and revenue beat expectations. A number of Wall Street analysts increased their price targets for the stock following the report, including Piper Jaffray's Gene Munster, who hiked his target to a "Street-high" $170 per share. Facebook management made only one mention of macro concerns for the business in 2016, significantly different than Apple's (AAPL) earnings call on Tuesday night, Munster pointed out... Caterpillar (CAT) reported better than expected quarterly earnings, excluding certain items, but its revenue came in below the consensus forecast and the heavy equipment maker warned that it does not anticipate an improvement in the world economy or commodity prices in 2016. The stock, which had declined almost 20% in the last three months prior to this morning's report, rebounded 4.7% to $61.08 after the company jumped over the lowered bar that had been set by bearish analysts... Under Armour (UA), which had similarly been the focus of concern recently for some bearish analysts, posted better than expected results on the top and bottom line and backed its fiscal year revenue forecast, proving its doubters wrong and sending its share rocketing up 22.5% to $84.00. MAJOR MOVERS: Among the notable gainers were Intrexon (XON), Inovio (INO) and Cerus (CERS), which gained a respective 10%, 7.6% and 1.4% as the ongoing Zika virus scare brought attention to the companies' efforts fighting the illness. Also higher were SolarCity (SCTY), Sunrun (RUN) and Vivint Solar (VSLR), with the solar stocks jumping 8.5%, 20.5% and 3.6%, respectively, after the California Public Utilities Commission approved new net-metering rules. Meanwhile, Eagle Pharmaceuticals (EGRX) rose 12.2% to $74.44 after announcing commercial availability of its Bendeka injection in partnership with Teva (TEVA). Among the noteworthy losers was Yahoo (YHOO), which lost 3.2% to $28.75 despite a pre-market spike after SpringOwl Asset Management urged the company to seek an investment from a strategic partner. The news was also followed by reports that CEO Marissa Mayer has started restructuring efforts with an "invest/maintain/kill" list, as well as news that Verizon (VZ) denied a report that it had bid for the company's core Internet business. Also lower were OSI Systems (OSIS), Qualcomm (QCOM) and eBay (EBAY), which fell a respective 31.8%, 8.3% and 12.5% following their quarterly earnings reports. INDEXES: The Dow rose 125.18, or 0.79%, to 16,069.64, the Nasdaq gained 38.51, or 0.86%, to 4,506.68, and the S&P 500 advanced 10.41, or 0.55%, to 1,893.36.
10:13 EDTALKSOptions with decreasing implied volatility
Subscribe for More Information
January 27, 2016
08:16 EDTXONFibrocell highlights pipeline accomplishments
Subscribe for More Information
January 26, 2016
10:06 EDTALKSOptions with decreasing implied volatility
Options with decreasing implied volatility: SRPT GNC ALKS CALM NFLX CREE FFIV COH ISRG IBM
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use